Oxford Cannabinoid Tech.Holdings Investor Presentation and Q&A -- Programmes update
12 Juli 2023 - 8:00AM
RNS Non-Regulatory
TIDMOCTP
Oxford Cannabinoid Tech.Holdings
12 July 2023
Oxford Cannabinoid Technologies Holdings plc
("OCTP" or the "Company")
Investor Presentation and Q&A - Programmes update
OCTP will host a live presentation and Q&A via the Investor
Meet Company platform at 16.00 BST on Wednesday 19 July 2023, open
to all existing and potential shareholders.
Recently appointed Chief Medical Officer, Dr Tim Corn and Chief
Scientific Officer, Dr Valentino Parravicini, will discuss
developments across the Company's portfolio.
Investors can sign up to Investor Meet Company for free and add
to meet Oxford Cannabinoid Technologies Holdings plc via:
https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor
Investors who already follow OCTP on the Investor Meet Company
platform will automatically receive an invitation to the event.
The Directors of the Company accept responsibility for the
content of this announcement.
Enquiries:
Oxford Cannabinoid Technologies Holdings +44 (0)20 3034 2820
plc clarissa@oxcantech.com
Clarissa Sowemimo-Coker (CEO)
Axis Capital Markets Limited
Richard Hutchison +44 (0)20 3026 0320
Walbrook PR Limited
Paul Vann +44 (0)20 7933 8780
Nick Rome +44 (0)7768 807631
Joe Walker oxcantech@walbrookpr.com
About Oxford Cannabinoid Technologies Holdings Plc:
Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the
holding company of Oxford Cannabinoid Technologies Ltd (together
the "Group"), a pharmaceutical Group developing prescription
cannabinoid medicines targeting the U$ multi-billion global pain
market.
OCTP currently has a portfolio of four drug development
programmes. Its lead compound, OCT461201, will initially target
neuropathic and visceral pain (including irritable bowel syndrome
("IBS") and chemotherapy induced peripheral neuropathy ("CIPN")),
with the Phase I clinical trial, aimed at demonstrating safety and
tolerability. Trial results are expected in Q3 2023. The global
market for CIPN alone is currently valued at US$1.61bn and is
forecast to reach US$2.37bn by the year 2027.
OCTP's drug development pipeline comprises both natural and
synthetic compounds, and includes compounds targeting trigeminal
neuralgia, a severe type of face pain, and cannabinoid derivatives
targeting pain and potentially other therapeutic areas. Having
established an exclusive license agreement with Canopy Growth
Corporation for their entire pharmaceutical cannabinoid derivative
library, OCTP now has a portfolio of almost five hundred
derivatives and intellectual property rights including fourteen
patent families and associated research data.
OCTP has a clearly defined path to commercialisation, revenues
and growth. The Group is developing drug candidates through
clinical trials to gain regulatory approval (FDA/MHRA/EMA) that
will enable medical professionals to prescribe them with
confidence. OCTP's portfolio aims to balance risk, value and time
to market, whilst ensuring market exclusivity around all its key
activities.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAMZGMNGMRGFZZ
(END) Dow Jones Newswires
July 12, 2023 02:00 ET (06:00 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
Von Mai 2023 bis Mai 2024